Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2013 Mar 26;11013:5223-8. doi: 10.1073/pnas.1214530110.
Show Gene links
Show Anatomy links
Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.
Woodward OM
,
Tukaye DN
,
Cui J
,
Greenwell P
,
Constantoulakis LM
,
Parker BS
,
Rao A
,
Köttgen M
,
Maloney PC
,
Guggino WB
.
???displayArticle.abstract???
The multidrug ATP-binding cassette, subfamily G, 2 (ABCG2) transporter was recently identified as an important human urate transporter, and a common mutation, a Gln to Lys substitution at position 141 (Q141K), was shown to cause hyperuricemia and gout. The nature of the Q141K defect, however, remains undefined. Here we explore the Q141K ABCG2 mutation using a comparative approach, contrasting it with another disease-causing mutation in an ABC transporter, the deletion of Phe-508 (ΔF508) in the cystic fibrosis transmembrane conductance regulator (CFTR). We found, much like in ΔF508 CFTR, that the Q141K mutation leads to instability in the nucleotide-binding domain (NBD), a defect that translates to significantly decreased protein expression. However, unlike the CFTR mutant, the Q141K mutation does not interfere with the nucleotide-binding domain/intracellular loop interactions. This investigation has also led to the identification of critical residues involved in the protein-protein interactions necessary for the dimerization of ABCG2: Lys-473 (K473) and Phe-142 (F142). Finally, we have demonstrated the utility of using small molecules to correct the Q141K defect in expression and function as a possible therapeutic approach for hyperuricemia and gout.
Balch,
Adapting proteostasis for disease intervention.
2008, Pubmed
Balch,
Adapting proteostasis for disease intervention.
2008,
Pubmed
Basseville,
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
2012,
Pubmed
Bergamini,
Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure.
2009,
Pubmed
Denning,
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.
1992,
Pubmed
,
Xenbase
Edwards,
The role of hyperuricemia and gout in kidney and cardiovascular disease.
2008,
Pubmed
Furukawa,
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
2009,
Pubmed
Gaffo,
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
2009,
Pubmed
Guggino,
Gates of Janus: cystic fibrosis and diarrhea.
1994,
Pubmed
Guggino,
New insights into cystic fibrosis: molecular switches that regulate CFTR.
2006,
Pubmed
Henriksen,
Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
2005,
Pubmed
Hoelen,
The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain.
2010,
Pubmed
Hutt,
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
2010,
Pubmed
Ichida,
Decreased extra-renal urate excretion is a common cause of hyperuricemia.
2012,
Pubmed
Imai,
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
2002,
Pubmed
Johnson,
Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?
2009,
Pubmed
Johnson,
Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?
2009,
Pubmed
Kage,
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.
2002,
Pubmed
Kage,
Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
2005,
Pubmed
Kim,
Hyperuricemia and risk of stroke: a systematic review and meta-analysis.
2009,
Pubmed
Kondo,
Functional analysis of SNPs variants of BCRP/ABCG2.
2004,
Pubmed
Krasnov,
Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships.
2008,
Pubmed
Kwon,
Knockdown of NHERF1 enhances degradation of temperature rescued DeltaF508 CFTR from the cell surface of human airway cells.
2007,
Pubmed
Köttgen,
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.
2013,
Pubmed
Litman,
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.
2002,
Pubmed
Loo,
Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
2009,
Pubmed
Loo,
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
2005,
Pubmed
Matsuo,
Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.
2009,
Pubmed
McDevitt,
Purification and structural analyses of ABCG2.
2009,
Pubmed
Mendoza,
Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.
2012,
Pubmed
Mizuarai,
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
2004,
Pubmed
Morisaki,
Single nucleotide polymorphisms modify the transporter activity of ABCG2.
2005,
Pubmed
Nakagawa,
Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.
2011,
Pubmed
Ni,
Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.
2010,
Pubmed
Ni,
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
2010,
Pubmed
Ozvegy,
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
2001,
Pubmed
Pedemonte,
Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
2005,
Pubmed
Pillinger,
Hyperuricemia and gout: new insights into pathogenesis and treatment.
2007,
Pubmed
Rabeh,
Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.
2012,
Pubmed
Roxo-Rosa,
Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
2006,
Pubmed
Rubenstein,
In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
1997,
Pubmed
Saison,
Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
2012,
Pubmed
Serohijos,
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.
2008,
Pubmed
Shigeta,
BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.
2010,
Pubmed
Suaud,
4-Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells.
2011,
Pubmed
Teem,
Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast.
1993,
Pubmed
Thibodeau,
The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis.
2010,
Pubmed
Van Goor,
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
2006,
Pubmed
Wakabayashi-Nakao,
Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation.
2009,
Pubmed
Wang,
Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
2007,
Pubmed
Woodward,
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
2009,
Pubmed
,
Xenbase
Woodward,
ABCG transporters and disease.
2011,
Pubmed
Wright,
A 'complexity' of urate transporters.
2010,
Pubmed
Yu,
Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
2011,
Pubmed
Zelinski,
ABCG2 null alleles define the Jr(a-) blood group phenotype.
2012,
Pubmed
